Melanotan II is usually described as the tanning peptide, and it is sold for that and for erections. Most pages about it argue about whether it works. That is the wrong argument: there is a controlled study saying it does something, and the reasons to avoid it sit elsewhere. It belongs under sexual health, which is where its documented effects and its documented emergencies both are.
What melanotan II is
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone, the signal that drives pigment production in skin. It is not selective: it activates several melanocortin receptors at once, which is why one injection can darken skin, suppress appetite and produce an erection. The breadth is not a bonus feature. It is the reason the side effects are hard to separate from the effects.
The controlled study, which is positive
A double-blind, placebo-controlled crossover study published in 2000 enrolled ten men with erectile dysfunction and organic risk factors [1]. Each received melanotan II at 0.025 mg/kg subcutaneously and vehicle, twice each, with erections measured by real-time RigiScan over six hours. Melanotan II initiated subjectively reported erections in 12 of 19 injections, against 1 of 21 placebo doses. Mean rigidity among responders was 6.9 on a scale of 0 to 10, and mean duration of tip rigidity above 80% was 45.3 minutes.
That is a small study, and it is a real one. Anyone claiming melanotan II does nothing is arguing with a placebo-controlled result. The useful questions are what else it does, and what you are actually injecting.
What is documented going wrong
A 2019 case report describes a man attending an emergency department at a tertiary urology center with acute priapism after subcutaneous melanotan injection [2]. It was diagnosed as low-flow priapism and managed with cavernosal aspiration, irrigation and intracavernosal phenylephrine. He avoided surgical shunting. At four-week follow-up he had not recovered erectile function.
A 2020 case report and review describes renal infarction attributed to melanotan II, and notes that melanotan II inducing rhabdomyolysis and renal failure had been described before [3]. The authors discuss a thrombotic mechanism and a possible direct toxic effect on renal tissue.
On the skin, a case report titled “Melanotan-associated melanoma” was published in the British Journal of Dermatology in 2011 [4]. A case report establishes that something happened once, not how often it happens, and that is worth stating as plainly as the report itself.
The same receptor family, the other route
The melanocortin system did produce an approved drug. Bremelanotide, a related melanocortin agonist, was taken through clinical trials and approved for hypoactive sexual desire disorder in premenopausal women, sold as Vyleesi. The pharmacology that makes melanotan II interesting is real enough to have carried a molecule all the way through a regulatory process.
The difference is not the chemistry. It is that one of them has a dose that was established in trials, a manufacturer who can be held to account and a label listing what it does. See the bremelanotide approval and the trials behind it and what its label reports for the comparison.
Where it stands with the FDA
Melanotan in any spelling appears on neither FDA bulk drug substance list: not in the 503A categories, updated May 14, 2026, and not in the 503B categories, updated March 21, 2025. There is no lawful route for a pharmacy to compound it. For how that framework works, see what makes a peptide legal to prescribe. For the compound this one is most often confused with, see PT-141.